title: Polymeric curcumin nanoparticle pharmacokinetics and metabolism in bile duct cannulated rats.
abstract: The objective of this study was to compare the pharmacokinetics and metabolism of polymeric nanoparticle-encapsulated (nanocurcumin) and solvent-solubilized curcumin formulations in Sprague-Dawley (SD) rats. Nanocurcumin is currently under development for cancer therapy. Since free, unencapsulated curcumin is rapidly metabolized and excreted in rats, upon intravenous (i.v.) administration of nanocurcumin only nanoparticle-encapsulated curcumin can be detected in plasma samples. Hence, the second objective of this study was to utilize the metabolic instability of curcumin to assess in vivo drug release from nanocurcumin. Nanocurcumin and solvent-solubilized curcumin were administered at 10 mg curcumin/kg by jugular vein to bile duct-cannulated male SD rats (n = 5). Nanocurcumin increased the plasma Cmax of curcumin 1749 fold relative to the solvent-solubilized curcumin. Nanocurcumin also increased the relative abundance of curcumin and glucuronides in bile but did not dramatically alter urine and tissue metabolite profiles. The observed increase in biliary and urinary excretion of both curcumin and metabolites for the nanocurcumin formulation suggested a rapid "burst" release of curcumin. Although the burst release observed in this study is a limitation for targeted tumor delivery, nanocurcumin still exhibits major advantages over solvent-solubilized curcumin, as the nanoformulation does not result in the lung accumulation observed for the solvent-solubilized curcumin and increases overall systemic curcumin exposure. Additionally, the remaining encapsulated curcumin fraction following burst release is available for tumor delivery via the enhanced permeation and retention effect commonly observed for nanoparticle formulations.
authors.affiliation: Nanotechnology Characterization Laboratory, Advanced Technology Program, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland 21702, United States.
authors.forename: Peng
authors.initials: P
authors.lastname: Zou
authors.forename: Lawrence
authors.initials: L
authors.lastname: Helson
authors.forename: Anirban
authors.initials: A
authors.lastname: Maitra
authors.forename: Stephan T
authors.initials: ST
authors.lastname: Stern
authors.forename: Scott E
authors.initials: SE
authors.lastname: McNeil
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D001646:Bile / Q000378:metabolism; D001652:Bile Ducts; D002404:Catheterization; D002626:Chemistry, Pharmaceutical; D003474:Curcumin / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D003692:Delayed-Action Preparations; D016503:Drug Delivery Systems; D004355:Drug Stability; D007275:Injections, Intravenous; D008297:Male; D053769:Nanocapsules / Q000737:chemistry; D011108:Polymers / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D012995:Solubility
chemical_list: D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D053769:Nanocapsules; D011108:Polymers; D003474:Curcumin
references.citation: J Pharm Biomed Anal. 1997 Aug;15(12):1867-76
references.pmid: 9278892
references.citation: J Control Release. 2010 Sep 1;146(2):164-74
references.pmid: 20385183
references.citation: Pharm Res. 1993 Jul;10(7):1093-5
references.pmid: 8378254
references.citation: Drug Dev Ind Pharm. 2010 Oct;36(10):1225-34
references.pmid: 20545506
references.citation: Mol Nutr Food Res. 2007 Aug;51(8):932-8
references.pmid: 17628876
references.citation: J Drug Target. 1996;4(2):87-93
references.pmid: 8894968
references.citation: J Control Release. 2004 Apr 16;96(1):135-48
references.pmid: 15063036
references.citation: J Pharm Sci. 2010 Apr;99(4):1871-81
references.pmid: 19827133
references.citation: Expert Opin Drug Deliv. 2010 Jan;7(1):49-62
references.pmid: 20017660
references.citation: J Colloid Interface Sci. 2011 Feb 1;354(1):116-23
references.pmid: 21044788
references.citation: Drug Metab Dispos. 1982 Sep-Oct;10(5):499-504
references.pmid: 6128200
references.citation: Int J Nanomedicine. 2012;7:1723-35
references.pmid: 22619523
references.citation: Biochim Biophys Acta. 1993 Mar 10;1176(1-2):43-50
references.pmid: 8452878
references.citation: Langmuir. 2008 May 20;24(10):5213-7
references.pmid: 18257595
references.citation: Curr Pharm Des. 2006;12(36):4685-701
references.pmid: 17168772
references.citation: Nanoscale. 2011 Apr;3(4):1558-67
references.pmid: 21283869
references.citation: Oncotarget. 2012 Jun;3(6):640-50
references.pmid: 22791660
references.citation: J Control Release. 2009 Jan 5;133(1):11-7
references.pmid: 18950666
references.citation: Drug Metab Dispos. 1999 Apr;27(4):486-94
references.pmid: 10101144
references.citation: Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11394-9
references.pmid: 19564622
references.citation: J Nanobiotechnology. 2007 Apr 17;5:3
references.pmid: 17439648
references.citation: Biomaterials. 2010 Sep;31(25):6597-611
references.pmid: 20553984
references.citation: Mol Pharm. 2010 Feb 1;7(1):86-93
references.pmid: 19886674
references.citation: Mol Pharm. 2012 Feb 6;9(2):248-60
references.pmid: 22204437
references.citation: Int J Pharm. 2011 Sep 15;416(1):331-8
references.pmid: 21729743
references.citation: Annu Rev Pharmacol Toxicol. 2012;52:481-503
references.pmid: 22035254
references.citation: J Control Release. 2001 May 14;72(1-3):191-202
references.pmid: 11389998
references.citation: J Control Release. 2005 Mar 21;103(2):481-97
references.pmid: 15763628
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):105-11
references.pmid: 11815407
references.citation: Mol Cancer Ther. 2008 Dec;7(12):3878-88
references.pmid: 19074860
references.citation: Drug Discov Today. 2012 Jan;17(1-2):71-80
references.pmid: 21959306
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1411-7
references.pmid: 18559556
references.citation: Drug Metab Dispos. 2012 Jul;40(7):1380-8
references.pmid: 22498894
references.citation: J Pharm Biomed Anal. 2011 Mar 25;54(4):807-11
references.pmid: 21126843
references.citation: Tex Heart Inst J. 2009;36(2):134-9
references.pmid: 19436807
references.citation: Mol Pharm. 2009 Jan-Feb;6(1):190-201
references.pmid: 19035785
references.citation: Mol Cancer Ther. 2010 Aug;9(8):2255-64
references.pmid: 20647339
references.citation: Cancer Res. 2010 Jun 1;70(11):4443-52
references.pmid: 20460537
references.citation: Cancer Prev Res (Phila). 2011 Aug;4(8):1158-71
references.pmid: 21546540
references.citation: J Basic Clin Physiol Pharmacol. 2006;17(4):231-44
references.pmid: 17338279
references.citation: Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):10980-5
references.pmid: 21690347
references.citation: Sci Transl Med. 2012 Apr 4;4(128):128ra39
references.pmid: 22491949
references.citation: J Agric Food Chem. 2007 Jan 24;55(2):538-44
references.pmid: 17227090
references.citation: PLoS One. 2010 Sep 30;5(9):
references.pmid: 20927340
references.citation: Food Chem. 2011 Aug 1;127(3):918-25
references.pmid: 25214079